Want to see HK:2158 full AI Analyst Report?
Top Page
Yidu Tech, Inc.
(2158)
Select Model
Select Model
Rating:52Neutral
Price Target:
HK$3.00
▼(-46.24% Downside)
Action:Reiterated
Date:08/25/26
The score is driven primarily by improving financial performance in 2026 and a low-debt balance sheet, which reduces solvency risk. However, the overall rating is held back by weak technical momentum (downtrend across key moving averages with negative MACD) and a high P/E valuation that requires more consistent operating profitability and cash-flow stability.
Positive Factors
Low Leverage
Very low leverage reduces refinancing and solvency risk while preserving financial flexibility. The stable equity base also provides a cushion for continued investment in healthcare data and AI capabilities, helping the company withstand operating volatility over the next several quarters.
Negative Factors
Negative Core Operating Profit
Negative operating profit and EBITDA show that the latest net income has not yet translated into sustained earnings power from core operations. This weakens confidence in margin durability and means the company still needs better operating leverage or cost discipline to establish a robust profit base.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
Very low leverage reduces refinancing and solvency risk while preserving financial flexibility. The stable equity base also provides a cushion for continued investment in healthcare data and AI capabilities, helping the company withstand operating volatility over the next several quarters.
Read all positive factors
Yidu Tech, Inc. (2158) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$3.05B
Dividend Yield1.4%
Average Volume (3M)1.73M
Price to Earnings (P/E)36.9
Beta (1Y)1.82
Revenue Growth16.87%
EPS GrowthN/A
CountryHK
Employees754
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)0.07
Shares Outstanding1,072,892,600
10 Day Avg. Volume1,416,520
30 Day Avg. Volume1,730,496
Financial Highlights & Ratios
PEG Ratio-0.40
Price to Book (P/B)1.25
Price to Sales (P/S)5.73
P/FCF Ratio-87.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.08
Revenue Forecast (FY)HK$972.31M
Yidu Tech, Inc. Business Overview & Revenue Model
Company Description
Yidu Tech Inc. is a technology company that develops and deploys healthcare solutions leveraging big data and artificial intelligence. Its operations extend across Mainland China, Brunei, and other global regions. The company's business activities...
How the Company Makes Money
Yidu Tech makes money primarily by selling technology-enabled services and software/platform solutions to customers in the pharmaceutical/life-sciences sector and the healthcare provider sector. Its revenue model generally includes: (1) solutions ...
Yidu Tech, Inc. Financial Statement Overview
Summary
Income Statement
46
Neutral
Balance Sheet
78
Positive
Cash Flow
52
Neutral
| Breakdown | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 790.51M | 714.98M | 807.08M | 804.70M | 1.24B |
| Gross Profit | 288.01M | 239.18M | 339.44M | 274.50M | 396.89M |
| EBITDA | -53.51M | -89.62M | -170.77M | -579.98M | -715.70M |
| Net Income | 70.15M | -117.79M | -194.94M | -627.97M | -762.32M |
Balance Sheet | |||||
| Total Assets | 4.30B | 4.69B | 4.82B | 4.91B | 4.72B |
| Cash, Cash Equivalents and Short-Term Investments | 2.22B | 3.30B | 3.70B | 3.75B | 3.77B |
| Total Debt | 71.09M | 129.54M | 95.20M | 14.13M | 52.16M |
| Total Liabilities | 612.04M | 711.37M | 732.21M | 755.36M | 715.34M |
| Stockholders Equity | 3.63B | 3.92B | 4.02B | 4.08B | 3.99B |
Cash Flow | |||||
| Free Cash Flow | -51.63M | -350.78M | -367.20M | -374.60M | -672.14M |
| Operating Cash Flow | -22.00M | -248.81M | -326.38M | -357.01M | -614.68M |
| Investing Cash Flow | -257.82M | 116.71M | 466.90M | -2.34B | 3.39B |
| Financing Cash Flow | -363.06M | 20.04M | 82.21M | 361.45M | -35.23M |
Yidu Tech, Inc. Technical Analysis
Negative
5.58
Price Trends
3.43
Negative
4.09
Negative
4.90
Negative
Market Momentum
-0.17
Negative
36.85
Neutral
67.35
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2158, the sentiment is Negative. The current price of 5.58 is above the 20-day moving average (MA) of 3.05, above the 50-day MA of 3.43, and above the 200-day MA of 4.90, indicating a bearish trend. The MACD of -0.17 indicates Negative momentum. The RSI at 36.85 is Neutral, neither overbought nor oversold. The STOCH value of 67.35 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2158.
Yidu Tech, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | HK$4.67B | 11.63 | 7.05% | 4.98% | 6.47% | 8.10% | |
57 Neutral | HK$11.76B | 20.98 | 4.62% | 160.60% | 7.92% | 152.75% | |
52 Neutral | HK$3.05B | 36.94 | 1.88% | 1.40% | 16.87% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | HK$931.99M | -18.57 | -1.56% | 10.61% | 7.95% | 60.86% | |
51 Neutral | HK$820.84M | -45.46 | -5.98% | ― | -3.77% | 73.89% |
* Healthcare Sector Average
HK:2158
Yidu Tech, Inc.
2.86
-2.77
-49.21%
HK:1833
Ping An Healthcare and Technology Company
5.44
-8.30
-60.41%
HK:9960
Kindstar Globalgene Technology, Inc.
0.90
-0.30
-25.42%
HK:2192
Medlive Technology Co., Ltd.
6.31
-3.81
-37.66%
HK:9686
NEUSOFT XIKANG HOLDINGS INC.
0.98
0.03
2.63%
HK:2506
Xunfei Healthcare Technology Co., Ltd.
64.15
-23.65
-26.94%
Yidu Tech, Inc. Corporate Events
Yidu Tech Wins RMB13.29 Million Hospital Big Data Platform Contract
Oct 26, 2026
Yidu Tech Inc., a Hong Kong-listed healthcare AI and big data company, specializes in intelligent decision-support solutions for hospitals, pharmaceutical firms, insurers and patients in China. Its platforms leverage models trained on real-world d...
Yidu Tech Uses Collateralised Loan to Boost Treasury Returns
Oct 9, 2026
Yidu Tech Inc. has entered into a collateralised loan product with Goldman Sachs, under which the company acted as lender and advanced a USD 65 million loan secured by Singapore government or Monetary Authority bonds. The four-month product, funde...
Yidu Tech Wins RMB14.9 Million Infectious Disease AI Projects in Xi’an
Sep 28, 2026
Yidu Tech Inc. announced that its affiliate Yidu Cloud (Beijing) Technology has successfully won bids for multiple infectious disease technology projects at The First Affiliated Hospital of the Medical School of Xi’an Jiaotong University. Th...
Yidu Tech Wins RMB3.57 Million Geriatric Health Innovation Project Bid
Sep 14, 2026
Yidu Tech Inc. announced that its affiliate Yidu Cloud (Beijing) Technology has won a bid to build an innovation and translation project focused on ageing and health for the National Clinical Research Center for Geriatric Diseases at Xiangya Hospi...
Yidu Tech Wins RMB3.57 Million AI Data Platform Upgrade Contract at Shanghai Pulmonary Hospital
Sep 9, 2026
Yidu Tech Inc. announced that its affiliate Yidu Cloud (Beijing) Technology Co., Ltd. has won a bid to undertake the domestication, adaptation and upgrade of the data platform at Shanghai Pulmonary Hospital, a project valued at about RMB3.57 milli...
Yidu Tech Shareholders Back All AGM Resolutions, Approve Dividend and Capital Mandates
Aug 28, 2026
Yidu Tech Inc. held its annual general meeting in Beijing on August 28, 2026, where shareholders approved all resolutions by poll, including the adoption of audited financial statements for the year ended March 31, 2026 and the declaration of a fi...
Yidu Tech Reshapes Board and Committee Roles to Bolster Governance
Aug 28, 2026
Yidu Tech Inc. has updated the composition of its board of directors effective 28 August 2026, confirming three executive directors, including Chairlady Gong Yingying and CEO Xu Jiming, alongside three independent non-executive directors. The boar...
Yidu Tech Unit Wins RMB8.6 Million Hospital IT Infrastructure Contract
Aug 10, 2026
Yidu Tech Inc. has announced that its affiliate Yidu Cloud (Beijing) Technology Co., Ltd. has won the bid to build the IT infrastructure for the Tongzhou campus of Capital Children’s Medical Center, affiliated with Capital Medical University...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.